Menu
Montecito
American Riviera
Loading...
You are here:  Home  >  Biotech  -  Page 3
Latest

Arcutis starts new Phase 3 trial

By   /  Friday, August 27th, 2021  /  Banking & Finance, Biotech, East Ventura County, Latest news, Tri-County Economy, Tri-County Public Companies  /  Comments Off on Arcutis starts new Phase 3 trial

Arcutis Biotherapeutics announced Aug. 25 that it has enrolled the first patient in a Phase 3 clinical trial to evaluate ARQ-154, its topical foam, as a treatment for scalp and body psoriasis. The foam is a once-daily formulation of roflumilast, a phosphodiesterase type 4 inhibitor that the company is developing to treat two skin conditions: Read More →

Read More →
Latest

Revenue and losses both growing at MannKind

By   /  Tuesday, August 17th, 2021  /  Banking & Finance, Biotech, Central Coast Health Watch, Earnings, East Ventura County, Latest news, Technology, Tri-County Economy, Tri-County Public Companies  /  Comments Off on Revenue and losses both growing at MannKind

MannKind saw a significant rise in revenue thanks to its product Afrezza, but its net loss in the second quarter of fiscal year 2021 also rose significantly as the company tried to pay down its debt. The Westlake Village biotech company released its earnings after the markets closed on Aug. 11. It opened the next Read More →

Read More →
Latest

Atara losses grew in Q2

By   /  Monday, August 9th, 2021  /  Banking & Finance, Biotech, Earnings, East Ventura County, Latest news, Technology, Tri-County Economy, Tri-County Public Companies  /  Comments Off on Atara losses grew in Q2

Atara Biotherapeutics swallowed more losses in the second quarter of 2021, as the early-stage company hopes for good news for its tab-cel therapy in early 2022. Atara, an immunotherapy biotech company based in South San Francisco with some of its major operations in Thousand Oaks, had a net loss of $83.7 million in the second Read More →

Read More →
Latest

Amgen shrugs off tough quarter, announces plans for new plant in North Carolina

By   /  Friday, August 6th, 2021  /  Banking & Finance, Biotech, Earnings, East Ventura County, Latest news, Subscriber content, Technology, Tri-County Economy, Tri-County Public Companies  /  Comments Off on Amgen shrugs off tough quarter, announces plans for new plant in North Carolina

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen reports Q2 earnings decline

By   /  Tuesday, August 3rd, 2021  /  Banking & Finance, Biotech, Earnings, East Ventura County, Latest news, Tri-County Economy, Tri-County Public Companies  /  Comments Off on Amgen reports Q2 earnings decline

Amgen saw a 73% decline in net earnings in the second quarter of 2021, the company announced Aug. 3. Thousand Oaks-based Amgen, one of the world’s largest biotechnology companies, reported earnings per share of 81 cents for the quarter ended June 30, down from $3.05 per share in the same quarter last year. According to Read More →

Read More →
Latest

With merger, ImmPact Bio plans growth and a move to LA

By   /  Friday, July 30th, 2021  /  Biotech, East Ventura County, Latest news, Subscriber content, Technology, Top Stories, Tri-County Economy, West Ventura County  /  Comments Off on With merger, ImmPact Bio plans growth and a move to LA

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen to buy biotech startup TeneoBio

By   /  Tuesday, July 27th, 2021  /  Banking & Finance, Biotech, East Ventura County, Latest news, left, Top Stories, Tri-County Economy, Tri-County Public Companies  /  Comments Off on Amgen to buy biotech startup TeneoBio

Amgen announced July 27 that it plans to buy a privately held Bay Area biotech company called TeneoBio in an all-cash deal worth as much as $2.5 billion. The deal is expected to close in the second half of this year and calls for Amgen to pay $900 million up front for all outstanding shares Read More →

Read More →